The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 378898086 | ||
| 003 | CHVBK | ||
| 005 | 20180305123511.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 161128e20041201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1515/CCLM.2004.258 |2 doi |
| 035 | |a (NATIONALLICENCE)gruyter-10.1515/CCLM.2004.258 | ||
| 245 | 0 | 4 | |a The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers |h [Elektronische Daten] |c [Markus Herrmann, Wolfgang Herrmann] |
| 520 | 3 | |a Purpose: Premature osteoporosis is a frequent problem in female athletes. Current concepts suggest that a disruption of the hypothalamic-pituitary axis leads to hypoestrogenism, which then causes amenorrhea and osteoporosis. However, the underlying mechanisms have been insufficiently investigated. Osteoprotegerin (OPG) and soluble TNF-α receptor antagonist ligand (sRANKL) regulate the balance of osteoblasts and osteoclasts. Their role in the pathogenesis of osteoporosis in female athletes has not been studied yet. Methods: We measured OPG and sRANKL in relation to biochemical bone markers [osteocalcin (OC), bone alkaline phosphatase (BAP), serum β-crosslaps (CTx)] and female sex hormones [estradiol (E2) and luteinizing hormone (LH)] in fastening blood samples from 25 female elite endurance athletes and 25 matched controls. Results: Athletes exhibited significantly higher levels of the bone resorption marker CTx than controls (0.61±0.26 vs. 0.44±0.15ng/ml). OPG and sRANKL were not changed. Subgroup analysis revealed that athletes using oral contraceptives [A-OCC(−)] had significantly higher levels of CTx (0.82±0.20 vs. 0.50±0.14ng/ml), BAP [37.3 (23.2-54.4) U/l vs. 25.2 (20.3-35.6) U/l] and OPG (3.4±0.8 vs. 2.7±0.8ng/ml) than controls who did not use oral contraceptives [C-OCC(−)]. While the difference for CTx exceeded the least significant change in this marker by approximately 30%, the differences for the bone formation markers OC and BAP were close to the least significant change. In athletes using oral contraceptives [A-OCC(+)] we found no differences compared to controls. Conclusions: A-OCC(−) athletes have increased bone turnover with a particular stimulation of bone resorption. The increased bone resorption is not accompanied by a shift of the OPG/sRANKL relationship towards an osteoclastogenic constellation. Since increased bone resorption was not detectable in A-OCC(+) athletes, it can be suggested that OCC use might protect bone health in female athletes. | |
| 540 | |a ©2004 by Walter de Gruyter Berlin New York | ||
| 690 | 7 | |a Medical equipment & techniques |2 nationallicence | |
| 690 | 7 | |a Medical diagnosis |2 nationallicence | |
| 690 | 7 | |a Diseases & disorders |2 nationallicence | |
| 690 | 7 | |a bone alkaline phosphatase (BAP) |2 nationallicence | |
| 690 | 7 | |a exercise |2 nationallicence | |
| 690 | 7 | |a osteocalcin (OC) |2 nationallicence | |
| 690 | 7 | |a osteoprotegerin (OPG) |2 nationallicence | |
| 690 | 7 | |a serum β-crosslaps (CTx) |2 nationallicence | |
| 690 | 7 | |a soluble TNF-α-receptor antagonist ligand (sRANKL) |2 nationallicence | |
| 700 | 1 | |a Herrmann |D Markus |u Department of Clinical Chemistry and Laboratory Medicine, University Hospital of Saarland, Homburg/Saar, Germany |4 aut | |
| 700 | 1 | |a Herrmann |D Wolfgang |u Department of Clinical Chemistry and Laboratory Medicine, University Hospital of Saarland, Homburg/Saar, Germany |4 aut | |
| 773 | 0 | |t Clinical Chemical Laboratory Medicine |d Walter de Gruyter |g 42/12(2004-12-01), 1384-1389 |x 1434-6621 |q 42:12<1384 |1 2004 |2 42 |o cclm | |
| 856 | 4 | 0 | |u https://doi.org/10.1515/CCLM.2004.258 |q text/html |z Onlinezugriff via DOI |
| 908 | |D 1 |a research article |2 jats | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1515/CCLM.2004.258 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Herrmann |D Markus |u Department of Clinical Chemistry and Laboratory Medicine, University Hospital of Saarland, Homburg/Saar, Germany |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Herrmann |D Wolfgang |u Department of Clinical Chemistry and Laboratory Medicine, University Hospital of Saarland, Homburg/Saar, Germany |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Clinical Chemical Laboratory Medicine |d Walter de Gruyter |g 42/12(2004-12-01), 1384-1389 |x 1434-6621 |q 42:12<1384 |1 2004 |2 42 |o cclm | ||
| 900 | 7 | |b CC0 |u http://creativecommons.org/publicdomain/zero/1.0 |2 nationallicence | |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-gruyter | ||